Additionally, treatment with Maraviroc (Pfizer, New York, United States), a CCR5 antagonist approved by the FDA, improves motor recovery in rodent models of stroke and TBI by enhancing tissue preservation in the brain, attenuating inflammatory responses, and upregulating the levels of cognition-related signaling molecules to promote neural plasticity (Villanueva, 2019; Friedman-Levi et al., 2021). Here, CCR5 is linked to stroke disorder.